Abstract
The amyloid cascade hypothesis is well known hypothesis describing the pathogenesis of Alzheimers disease (AD). On the basis of this hypothesis, inhibition of amyloid β-protein (Aβ) generation and aggregation, enhancement of extracellular Aβ removal, and Aβ vaccination are currently under investigation. Intracellular Aβ may be even more important than extracellular Aβ, since intraneuronal Aβ accumulation commonly precedes extracellular Aβ deposition in several familial AD-related mutant presenilin 1-transgenic mice. Various pathogenic mechanisms involving intracellular Aβ such as mitochondrial toxicity, proteasome impairment and synaptic damage have been suggested. Recently, we have reported that cytosolic Aβ42 accumulation leads to p53 mRNA expression and p53-related apoptosis. It was also reported that a novel chaperone protein, Aβ-related death-inducing protein (AB-DIP), regulates nuclear localization of intracellular Aβ42. Therefore, intraneuronal Aβ represents an alternative therapeutic target. While inhibition of Aβ production and anti-Aβ immunotherapies are likely to attenuate both intraneuronal and extracellular Aβ toxicity, more specific antiintraneuronal Aβ therapies should be useful. The focus of this article is to review the pathogenic mechanisms involving intracellular Aβ and advocate intracellular Aβ as an important therapeutic target in AD.
Keywords: Alzheimer's disease, amyloid β-protein, Aβ-related death-inducing protein, p53, apoptosis, proteasome
Current Alzheimer Research
Title: Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease
Volume: 5 Issue: 6
Author(s): Y. Ohyagi
Affiliation:
Keywords: Alzheimer's disease, amyloid β-protein, Aβ-related death-inducing protein, p53, apoptosis, proteasome
Abstract: The amyloid cascade hypothesis is well known hypothesis describing the pathogenesis of Alzheimers disease (AD). On the basis of this hypothesis, inhibition of amyloid β-protein (Aβ) generation and aggregation, enhancement of extracellular Aβ removal, and Aβ vaccination are currently under investigation. Intracellular Aβ may be even more important than extracellular Aβ, since intraneuronal Aβ accumulation commonly precedes extracellular Aβ deposition in several familial AD-related mutant presenilin 1-transgenic mice. Various pathogenic mechanisms involving intracellular Aβ such as mitochondrial toxicity, proteasome impairment and synaptic damage have been suggested. Recently, we have reported that cytosolic Aβ42 accumulation leads to p53 mRNA expression and p53-related apoptosis. It was also reported that a novel chaperone protein, Aβ-related death-inducing protein (AB-DIP), regulates nuclear localization of intracellular Aβ42. Therefore, intraneuronal Aβ represents an alternative therapeutic target. While inhibition of Aβ production and anti-Aβ immunotherapies are likely to attenuate both intraneuronal and extracellular Aβ toxicity, more specific antiintraneuronal Aβ therapies should be useful. The focus of this article is to review the pathogenic mechanisms involving intracellular Aβ and advocate intracellular Aβ as an important therapeutic target in AD.
Export Options
About this article
Cite this article as:
Ohyagi Y., Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898514
DOI https://dx.doi.org/10.2174/156720508786898514 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design
Medicinal Chemistry SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology The Prognosis of Pediatric AIDS in Serbia
Current HIV Research Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Retroperitoneal Cryptococcoma in a Case of Disseminated Cryptococcosis on Antifungal Maintenance Therapy
Current HIV Research Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Inflammation, Immunity, and Alzheimers Disease (Guest Editor: Terrence Town)]
CNS & Neurological Disorders - Drug Targets Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
Current Medicinal Chemistry Behçets Disease as an Autoinflammatory Disorder
Current Drug Targets - Inflammation & Allergy